Dedicated MR Imaging vs Surgical Staging of Peritoneal Carcinomatosis in Colorectal Cancer

Colorectal Cancer Clinical Trial

— DISCO  

Official title:

Dedicated MR Imaging vs Surgical Staging of Peritoneal Carcinomatosis in Colorectal Cancer Patients; a Multicenter Randomized Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04231175
• Other study ID #: M19DSC
• Status: Recruiting
• Phase: N/A
• Start date: October 28, 2019
• Est. completion date: October 28, 2023

Study information

• Verified date: January 2020
• Source: The Netherlands Cancer Institute
• Contact: Max Lahaye, PhD MD
• Phone: +31 20 512 1012
• Email: m.lahaye[@]nki.nl
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

MRI is a potentially powerful tool to reliably determine the intra-abdominal tumor load and relations with intra-abdominal organs. In recent years diffusion weighted MRI has proven its value as a highly sensitive technique to detect small malignant disease in a wide variety of cancers [1-3]. However, literature concerning the clinical impact of detecting peritoneal metastases with MRI is very limited. Therefore, there is a need for a large randomized multicenter trial to determine whether dedicated MRI can be used as a selection tool for CRS-HIPEC candidates in daily practice.

Description:

HYPOTHESIS Staging with dedicated MRI will lead to a reduction of staging laparoscopies and explorative laparotomies in colorectal patients with PM to evaluate whether they may benefit from CRS-HIPEC

OBJECTIVES The goal is to perform a multicenter randomized study to compare a less invasive diagnostic workup ARM A (with MRI and surgical inspection reserved for borderline operable cases on MRI) to the standard diagnostic workup (ARM B, without MRI, with surgical staging to determine resectability based on a MDT decision) of patients with (suspected) peritoneal metastases. Surgical staging laparoscopies may largely be replaced by MRI (only reserved as a problem solver for borderline operable cases in ARM A). If it will be proven that MRI is an accurate, robust and cost-effective staging tool than this will result in a more patient friendly diagnostic workup with less futile surgical procedures.

STUDY DESIGN 4-year multicenter randomized controlled trial

STUDY POPULATION N=272 patients suspected of synchronous or metachronous peritoneal metastases of colorectal origin who are considered for CRS-HIPEC after CT imaging.

EXPERIMENTAL (ARM A) CRS-HIPEC candidates are selected based on MRI and only in borderline cases a surgical inspection will be performed

CONTROL (ARM B) Standard work-up including computed tomography and surgical inspection as appropriate (based on a MDT decision).

MAIN STUDY PARAMETERS/ENDPOINTS

Primary outcome:

Number of preventable unnecessary laparoscopies and explorative laparotomies.

NATURE AND EXTENT OF THE BURDEN AND RISKS ASSOCIATED WITH PARTICIPATION, BENEFIT AND GROUP RELATEDNESS:

MRI is a standard diagnostic procedure without the use of radiation. The MR sequences, MR-contrast agents and Buscopan (to minimize peristaltic bowel movements) are all commonly used in daily clinical practice. In addition, patients will be asked to drink 1L of pineapple juice 1-2 hours before the MRI (to minimize signal in the bowel lumen and optimize image quality), which is standard procedure in many clinics for MRCP and MR enterography. By acting upon the MRI findings in the experimental arm A, could result into new risks as oppose to standard clinical practice. However by introducing the borderline group ('yellow light' group) to receive diagnostic laparoscopy will minimize the possibility of over-staging a patient that would have received a successful CRS/HIPEC in de control arm. In our internal pilot data of 87 patients considered for CRS/HIPEC, no patients with a PCI of above 24 ended up receiving successful CRS/HIPEC and only 4 of the 15 patients that could have been assigned to the borderline group (were the trail to have run at that time) received successful CRS/HIPEC.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 272
• Est. completion date: October 28, 2023
• Est. primary completion date: October 28, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with suspicion of colorectal peritoneal metastases and considered for CRS/HIPEC

• Age =18 years

• Written and signed informed consent

• WHO 0-2

• Able and willing to drink 1 liter of pineapple or blueberry juice

Exclusion Criteria:

• - Patients with contraindications for the MRI:

• Patients who have a heart pacemaker may not have an MRI scan

• Patients who have a metallic foreign body (metal sliver) in their body

• Patients with severe claustrophobia

• Ineligible to receive gadofosveset (Gadolinium) contrast (history of contrast allergy, impaired kidney function with a Glomerular Filtration Rate <30 ml/min/1.73m2)

• Ineligible to receive Buscopan

• Allergy for pineapple juice and blueberry juice.

• Patients with clinical contraindications for CRS/HIPEC

• Patients with radiological contra-indications for CRS/HIPEC observed on CT thorax/abdomen

• Massive mesenteric or small bowel involvement which would lead to short bowel syndrome if adequately resected

• Extra-peritoneal metastases for which CRS/HIPEC is not justifiable (such as lung metastases, skeletal metastases, and liver metastases)

• Inoperable retroperitoneal lymphadenopathy

• Patients with a known additional malignancy, unless o treated with curative intent at least five years ago. in situ cancers, basal cell carcinoma of the skin or squamous cell carcinoma of the skin that have undergone potentially curative therapy within the past five years

Related Conditions & MeSH terms

• Carcinoma
• Colorectal Cancer
• Colorectal Neoplasms
• MRI
• Peritoneal Carcinomatosis
• Peritoneal Neoplasms

Intervention

Diagnostic Test:
• DWI MRI of the pelvis, abdomen and thorax
Patients in Arm A will receive a MRI scan of their pelvis, abdomen, and thorax before possible surgery. During the MRI standard Gadolinium contrast agent and Buscopan is intravenously administered, which is standard clinical practice in abdominal MR imaging. Total scan time is 35 minutes and includes T2 weighted, T1 weighted, Diffusion weighted and dynamic contrast enhanced imaging of the abdomen and the thorax. The findings of this scan will be used to determine whether to proceed with CRS/HIPEC, DLS and then possibly CRS-HIPEC, or palliative care.

Locations

Country	Name	City	State
Netherlands	Antoni van Leeuwenhoek	Amsterdam

Sponsors (2)

Lead Sponsor	Collaborator
The Netherlands Cancer Institute	ZonMw: The Netherlands Organisation for Health Research and Development

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of preventable unnecessary laparoscopies and explorative laparotomies defined as:	(I) patients with a PCI<15 at laparoscopy or PCI>24 at laparotomy (II) incomplete CRS-HIPEC (R2A/R2B/open-close procedures)	4 weeks
Primary	Number of preventable unnecessary laparoscopies and explorative laparotomies defined as	(II) incomplete CRS-HIPEC (R2A/R2B/open-close procedures)	4 weeks
Secondary	- Number of additional extra-peritoneal findings	Number of additional extra-peritoneal findings	4 weeks
Secondary	- Number of early recurrences (with-in 6 months after R1 resection and HIPEC)	- Number of early recurrences (with-in 6 months after R1 resection and HIPEC)	6 months
Secondary	- Diagnostic performance of Peritoneal Cancer Index determined by MRI (MRI-PCI) to predict surgical Peritoneal Cancer Index (S-PCI).	- The Peritoneal Cancer Index (PCI) system reported by Sugerbaker [24] will be determined by indicating the presence of large (>5cm), moderate (<5cm - >0.5cm), small (<0.5cm) or no involvement in 13 abdominal regions	6 months
Secondary	- Inter-observer agreement between different readers for DW-MRI.	Readers will evaluate the following MR criteria that might result in an incomplete CRS with a confidence level score (0 to 5): MRI-PCI > 20; Extensive agglutinated intra-abdominal disease (stomach/liver/spleen/retrohepatic); Extensive serosa involvement (>1.5 m bowel resection needed); Extensive disease at diaphragmatic level (>1 cm in diameter); Extensive extra-abdominal disease (>1 cm in diameter) in patients without neoadjuvant treatment; Presence and location of intra-abdominal enlarged lymph nodes; Ascites > 500 ml; Overall resectability based on MRI findings	6 months
Secondary	Incremental cost-effectiveness ratio	The direct costs will include costs of standard treatment (chemotherapy and cytoreductive surgery), costs of diagnostic work-up (standard and MRI) and treatment of adverse events/surgical complications, follow-up visits, recurrences and palliative care (measured as possible within the trial period). From this the cost effectiveness will be determined.	6 months
Secondary	Quality of Life between diagnostic arms by EORTC-C30 -	The following questionnaire will be used to measure HRQoL in patients EORTC-C30. This will be completed at baseline, 3 & 6 months following randomisation.	6 months
Secondary	Quality of Life between diagnostic arms by EQ5D5L	The following questionnaire will be used to measure HRQoL in patients EQ5D5L. This will be completed at baseline, 3 & 6 months following	6 months